Passage Bio, Inc.

Historical 13F Holders

Symbol: PASG
CUSIP: 702712100
All holders as of: Q3 2025
Type: Equity
Class: COM

Reported Value, Excluding Options

Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 702712100 since 12/18/2024, newest first.

Filer	% of Class	Shares	Form	Filed
Lynx1 Capital Management LP 13D	21.0%	673,759	13D	7/2/2026 Event 6/25/2026
Lynx1 Capital Management LP	21.0%	673,759
Weston Nichols	21.0%	673,759
Lynx1 Capital Management LP 13G/A Amendment 3	19.6%	623,704	13G/A Amendment 3	11/14/2025 Event 9/30/2025
LYNX1 Capital Management LP	19.6%	623,704
Weston Nichols	19.6%	623,704
Orbimed Advisors LLC 13D/A Amendment 9	4.3%	132,473	13D/A Amendment 9	7/24/2025 Event 7/22/2025
Orbimed Advisors LLC	4.3%	132,473
Orbimed Capital GP VII LLC	4.3%	132,473
Orbimed Advisors LLC 13D/A Amendment 8	7.8%	243,878	13D/A Amendment 8	7/21/2025 Event 7/17/2025
Orbimed Advisors LLC	7.8%	243,878
Orbimed Capital GP VII LLC	7.8%	243,878
Orbimed Advisors LLC 13D/A Amendment 7	9.5%	5,923,534	13D/A Amendment 7	7/9/2025 Event 7/7/2025
Orbimed Advisors LLC	9.5%	5,923,534
Orbimed Capital GP VII LLC	9.5%	5,923,534
Orbimed Advisors LLC 13D/A Amendment 6	10.7%	6,650,000	13D/A Amendment 6	4/25/2025 Event 4/22/2025
Orbimed Advisors LLC	10.7%	6,650,000
Orbimed Capital GP VII LLC	10.7%	6,650,000
Lynx1 Capital Management LP 13G/A Amendment 2	15.0%	9,256,953	13G/A Amendment 2	2/14/2025 Event 12/31/2024
Lynx1 Capital Management LP	15.0%	9,256,953
Weston Nichols	15.0%	9,256,953
Orbimed Advisors LLC 13D/A Amendment 5	12.0%	7,404,869	13D/A Amendment 5	12/26/2024 Event 12/20/2024
Orbimed Advisors LLC	12.0%	7,404,869
Orbimed Capital GP VII LLC	12.0%	7,404,869
Orbimed Capital LLC	0%	0
Erste Asset Management GmbH 13G/A Amendment 1	4.4%	2,455,800	13G/A Amendment 1	11/14/2024 Event 3/31/2024
Erste Asset Management GmbH 13G	5.4%	2,960,800	13G	11/14/2024 Event 12/31/2023

13F Holders by Quarter

Period	Filings	Shares, Excl. Options	Value, Excl. Options	Options Value
2025 Q3	2	87.4 k	$702 k	$0
2025 Q2	42	35.1 M	$33.0 M	$16.2 k
2025 Q1	44	36.3 M	$12.8 M	$17.6 k
2024 Q4	48	37.6 M	$21.6 M	$5.99 k
2024 Q3	48	38.7 M	$27.1 M	$5.39 k
2024 Q2	50	40.3 M	$32.0 M	$6.91 k
2024 Q1	57	40.3 M	$54.4 M	$28.1 k
2023 Q4	58	32.8 M	$33.1 M	$1.72 k
2023 Q3	53	32.4 M	$21.3 M	$4.34 k
2023 Q2	58	33.4 M	$31.4 M	$1.60 k
2023 Q1	62	35.5 M	$34.0 M	$3.26 k
2022 Q4	71	37.5 M	$51.7 M	$25.5 k
2022 Q3	78	39.4 M	$49.3 M	$61.0 k
2022 Q2	89	42.2 M	$99.6 M	$0
2022 Q1	112	43.0 M	$133 M	$34.0 k
2021 Q4	107	43.7 M	$278 M	$316 k
2021 Q3	106	42.1 M	$419 M	$399 k
2021 Q2	104	44.6 M	$559 M	$217 k
2021 Q1	92	45.0 M	$786 M	$0
2020 Q4	72	32.0 M	$818 M	$0
2020 Q3	72	30.8 M	$403 M	$0
2020 Q2	67	31.6 M	$863 M	$0
2020 Q1	47	29.4 M	$462 M	$0